Paradigm Biopharmaceuticals Ltd
PAR
Company Profile
Business description
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
Contact
500 Collins Street
Level 15
MelbourneVIC3000
AUST: +61 396295566
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
stocks
3 "buy the dip" candidates with wide moats
Share price pullbacks can present an opportunity to buy high quality companies at attractive prices.
stocks
Undervalued ASX share hampered by delays in foreign expansion
A near monopoly in Australia pushes this company into global markets but progress has been slow.
stocks
Ask the analyst: Why has MinRes fallen so far?
Mineral Resources shares are down almost 50% year to date. Mark Taylor weighs in on some of the reasons why.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,450.90 | 64.30 | -0.76% |
| CAC 40 | 7,226.98 | 199.90 | -2.69% |
| DAX 40 | 19,033.64 | 414.96 | -2.13% |
| Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
| FTSE 100 | 8,025.77 | 99.42 | -1.22% |
| HKSE | 19,705.97 | 140.91 | -0.71% |
| NASDAQ | 19,281.40 | 17.36 | -0.09% |
| Nikkei 225 | 38,716.37 | 659.72 | -1.68% |
| NZX 50 Index | 12,674.49 | 74.87 | -0.59% |
| S&P 500 | 5,983.99 | 17.36 | -0.29% |
| S&P/ASX 200 | 8,193.40 | 62.20 | -0.75% |
| SSE Composite Index | 3,428.77 | 6.80 | 0.20% |